{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:48:51Z","timestamp":1791103731440,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.leukres.2011.05.014","type":"journal-article","created":{"date-parts":[[2011,6,19]],"date-time":"2011-06-19T04:45:06Z","timestamp":1308458706000},"page":"1212-1218","source":"Crossref","is-referenced-by-count":19,"title":["Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor"],"prefix":"10.1016","volume":"35","author":[{"given":"Wenjuan","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiejing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2011.05.014_bib0005","doi-asserted-by":"crossref","first-page":"104631","DOI":"10.1155\/2011\/104631","article-title":"Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications","volume":"2011","author":"Reikvam","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.leukres.2011.05.014_bib0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.yexmp.2008.09.004","article-title":"KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups","volume":"85","author":"Sritana","year":"2008","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.leukres.2011.05.014_bib0015","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S1471-4914(02)02316-X","article-title":"Hsp90 inhibitors as novel cancer chemotherapeutic agents","volume":"8","author":"Neckers","year":"2002","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.leukres.2011.05.014_bib0020","doi-asserted-by":"crossref","first-page":"24585","DOI":"10.1074\/jbc.270.41.24585","article-title":"Disruption of the Raf-1-hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association","volume":"270","author":"Schulte","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2011.05.014_bib0025","first-page":"1721","article-title":"Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition","volume":"52","author":"Whitesell","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2011.05.014_bib0030","doi-asserted-by":"crossref","first-page":"8324","DOI":"10.1073\/pnas.91.18.8324","article-title":"Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation","volume":"91","author":"Whitesell","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.leukres.2011.05.014_bib0035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002800050817","article-title":"The benzoquinone ansamycin 17-allylamino-17-demethoxy-geldanamycin binds to HSP90 and shares important biologic activities with geldanamycin","volume":"42","author":"Schulte","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2011.05.014_bib0040","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.leukres.2005.08.028","article-title":"Jianxiang Wang 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level","volume":"30","author":"Yu","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.05.014_bib0045","doi-asserted-by":"crossref","first-page":"10860","DOI":"10.1073\/pnas.95.18.10860","article-title":"ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR\/mSin3\/HDAC1 complex","volume":"95","author":"Wang","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.leukres.2011.05.014_bib0050","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1074\/jbc.M006864200","article-title":"Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein hsp90","volume":"276","author":"Xu","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2011.05.014_bib0055","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/1078-0432.CCR-06-1863","article-title":"Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer","volume":"13","author":"Solit","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2011.05.014_bib0060","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.exphem.2005.03.007","article-title":"STI 571 inhibition effect on Asn822Lys KIT-mediated signal transduction cascade","volume":"33","author":"Beghini","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2011.05.014_bib0065","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/10428190400007565","article-title":"The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia","volume":"46","author":"Larizza","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2011.05.014_bib0070","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.thj.6200168","article-title":"Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia","volume":"3","author":"Beghini","year":"2002","journal-title":"Hematol J"},{"key":"10.1016\/j.leukres.2011.05.014_bib0075","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2003-07-2477","article-title":"Neckers L.17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells","volume":"103","author":"Fumo","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.014_bib0080","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/sj.onc.1205184","article-title":"Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2","volume":"21","author":"Basso","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2011.05.014_bib0085","first-page":"355","article-title":"The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome","volume":"11","author":"An","year":"2000","journal-title":"Cell Growth Differ"},{"key":"10.1016\/j.leukres.2011.05.014_bib0090","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2174\/156800909789271486","article-title":"Heat shock protein 90 \u2013 a potential target in the treatment of human acute myelogenous leukemia","volume":"9","author":"Reikvam","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.leukres.2011.05.014_bib0095","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/sj.leu.2402409","article-title":"STI-571 must select for drug resistant cells but \u2018no cell breathes fire out of its nostrils like a dragon\u2019","volume":"16","author":"Blagosklonny","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.05.014_bib0100","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.leukres.2011.05.014_bib0105","doi-asserted-by":"crossref","first-page":"9153","DOI":"10.1158\/0008-5472.CAN-06-0165","article-title":"Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor","volume":"66","author":"Bauer","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2011.05.014_bib0110","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1200\/JCO.2005.09.119","article-title":"Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer","volume":"23","author":"Goetz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.05.014_bib0115","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1038\/sj.onc.1204336","article-title":"Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?","volume":"20","author":"Minucci","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2011.05.014_bib0120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1517\/14728222.10.1.51","article-title":"Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML","volume":"10","author":"Bruserud","year":"2006","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.leukres.2011.05.014_bib0125","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/leu.2010.276","article-title":"Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia","volume":"25","author":"Quint\u00e1s-Cardama","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.05.014_bib0130","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1179\/102453310X12647083620967","article-title":"Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia \u2013 a report of five cases","volume":"15","author":"Fredly","year":"2010","journal-title":"Hematology"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611002311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611002311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,2]],"date-time":"2018-12-02T01:51:25Z","timestamp":1543715485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212611002311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0145212611002311"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2011.05.014","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}